Once-Weekly HIV Pill Held Viral Suppression as Well as Daily Treatment in Two Phase 3 Trials
Merck and Gilead reported 48-week Phase 3 results for an investigational once-weekly HIV single tablet combining islatravir 2 mg and lenacapavir 300 mg. In ISLEND-1, 93.4% of switchers maintained viral suppression vs 92.4% on daily Biktarvy. In ISLEND-2, 95.2% vs 95.5%. No emergent resistance; hepatitis B vaccination matters. Data support regulatory submissions.
How this was made
The 30-second read
Why it matters
If regulators accept the data, a weekly oral option could shift treatment convenience and adherence dynamics versus daily single-tablet regimens. Near-term trading impact is sentiment-driven because the drug is not approved and key uncertainties remain (durability, resistance over longer follow-up, and hepatitis B eligibility).
Market read
Traders may price in incremental probability of regulatory progress for weekly HIV therapy, but should discount for investigational status and unresolved longer-term durability and resistance questions.
What to watch
Hepatitis B non-activity is a practical barrier for co-infected patients, and the article notes durability beyond one year and longer follow-up resistance data are still unknown.
Background
The article describes Phase 3 results for an investigational once-weekly oral single-tablet combining islatravir (Merck) and lenacapavir (Gilead), presented at the International AIDS Conference and with ISLEND-1 published in NEJM.
Ticker impact
Merck’s islatravir, co-formulated in a once-weekly HIV pill, showed noninferior viral suppression versus daily therapy over 48 weeks in Phase 3 trials.
Moderate upside bias for MRK on trial-readout sentiment, with follow-through likely dependent on regulatory milestones and longer follow-up.
The article provides specific efficacy and safety outcomes and states the data will support regulatory submissions, which is a tangible catalyst. However, the drug is not approved and durability beyond 48 weeks is not established.
Gilead’s lenacapavir in a once-weekly HIV pill maintained viral suppression versus daily regimens in two Phase 3 trials, with no emergent resistance detected at 48 weeks.
Potentially supportive for GILD sentiment, but likely capped until approval, real-world adherence data, and longer-term resistance/durability are clearer.
The article discloses concrete trial endpoints, adverse event rates, and resistance observations, plus a stated intent to use data for regulatory submissions. Still, the product is investigational and hepatitis B caveats could affect uptake.
Market effects
Reinforces competitive momentum in long-acting or less-frequent HIV regimens, potentially raising expectations for weekly oral single-tablet options.
Limited direct regional impact; primarily global HIV therapeutics sentiment.
Could influence global HIV treatment standards and payer discussions if regulatory review proceeds successfully.
Counterpoint
Noninferiority at 48 weeks in highly selected, already-suppressed patients may not translate to broader real-world adherence and resistance outcomes, especially with a weekly dosing failure mode.
Key entities
- companyMerck
Develops islatravir, a component of the investigational once-weekly HIV pill; the article cites Phase 3 efficacy and safety results supporting regulatory submissions.
- companyGilead Sciences
Develops lenacapavir, a component of the investigational once-weekly HIV pill; the article cites Phase 3 efficacy and safety results supporting regulatory submissions.
- clinical_trialISLEND-1
Double-blind Phase 3 switch study comparing weekly pill versus continued daily Biktarvy over 48 weeks.
- clinical_trialISLEND-2
Open-label Phase 3 switch study across multiple daily regimens over 48 weeks.
- regulatory_eventFDA clinical hold (2021)
Islatravir development was paused due to CD4/lymphocyte declines at higher doses, later resumed at lower doses including the 2 mg weekly dose.
